A monte carlo dosimetry study of vaginal 192Ir brachytherapy applications with a shielded cylindrical applicator set.

A durable recommendation for brachytherapy treatment planning systems to account for the effect of tissue, applicator and shielding material heterogeneities exists. As different proposed approaches have not been integrated in clinical treatment planning routine yet, currently utilized systems disregard or, most commonly, do not fully account for the aforementioned effects. Therefore, it is of interest to evaluate the efficacy of current treatment planning in clinical applications susceptible to errors due to heterogeneities. In this work the effect of the internal structure as well as the shielding used with a commercially available cylindrical shielded applicator set (Nucletron part # 084.320) for vaginal and rectum treatments is studied using three-dimensional Monte Carlo simulation for a clinical treatment plan involving seven source dwell positions of the classic microSelectron HDR 192Ir source. Results are compared to calculations of a treatment planning system (Plato BPS v.14.2.7), which assumes homogeneous water medium and applies a constant, multiplicative transmission factor only at points lying in the shadow of the shield. It is found that the internal structure of the applicator (which includes stainless steel, air and plastic materials) with no shield loaded does not affect the dose distribution relative to homogeneous water. In the unshielded side of the applicator with a 90 degrees, 180 degrees, or 270 degrees tungsten alloy shield loaded, an overestimation of treatment planning system calculations relative to Monte Carlo results was observed which is both shield and position dependent. While significant (up to 15%) at increased distances, which are not of major clinical importance, this overestimation does not affect dose prescription distances by more than 3%. The inverse effect of approx. 3% dose increase at dose prescription distances is observed for stainless steel shields. Regarding the shielded side of the applicator, it is shown that the default treatment planning system transmission factors for tungsten alloy result in a consistent dose over-estimation thus constituting a safe approach given the nature of associated clinical applications. Stainless steel is shown to be an ineffective shielding material with transmission factors reaching up to 0.68 at increased distances irrespective of shield geometry.

[1]  D Baltas,et al.  The effect of patient inhomogeneities in oesophageal 192Ir HDR brachytherapy: a Monte Carlo and analytical dosimetry study. , 2004, Physics in medicine and biology.

[2]  D Baltas,et al.  Evaluation of a TG-43 compliant analytical dosimetry model in clinical 192Ir HDR brachytherapy treatment planning and assessment of the significance of source position and catheter reconstruction uncertainties. , 2004, Physics in medicine and biology.

[3]  J. Williamson,et al.  Analytical approach to heterogeneity correction factor calculation for brachytherapy. , 1998, Medical physics.

[4]  J F Williamson,et al.  Dose calculations about shielded gynecological colpostats. , 1990, International journal of radiation oncology, biology, physics.

[5]  J F Williamson,et al.  On the validity of the superposition principle in dose calculations for intracavitary implants with shielded vaginal colpostats. , 2001, Medical physics.

[6]  J. Williamson,et al.  Two-dimensional scatter integration method for brachytherapy dose calculations in 3D geometry. , 1997, Physics in medicine and biology.

[7]  N. van Wieringen,et al.  The development of PdNi thermoseeds for interstitial hyperthermia. , 1995, Medical physics.

[8]  K R Russell,et al.  Dose calculation in brachytherapy for a source using a primary and scatter dose separation technique , 1996, Physics in medicine and biology.

[9]  A Ahnesjö,et al.  Point kernels and superposition methods for scatter dose calculations in brachytherapy. , 2000, Physics in medicine and biology.

[10]  C. Ling,et al.  Measurement of dose distribution around Fletcher-Suit-Delcos colpostats using a Therados radiation field analyzer (RFA-3). , 1984, Medical physics.

[11]  W. Lutz,et al.  Comparison of calculated and measured heterogeneity correction factors for 125I, 137Cs, and 192Ir brachytherapy sources near localized heterogeneities. , 1993, Medical physics.

[12]  Jeffrey F. Williamson,et al.  Accelerated Monte Carlo based dose calculations for brachytherapy planning using correlated sampling. , 2002 .

[13]  C Kolotas,et al.  Comparison of calibration procedures for 192Ir high-dose-rate brachytherapy sources. , 1999, International journal of radiation oncology, biology, physics.

[14]  G. Glasgow,et al.  Specific gamma-ray constant and exposure rate constant of 192Ir. , 1979, Medical physics.

[15]  L. Dewerd,et al.  Brachytherapy dosimetry of 125I and 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code. , 2003, Medical physics.

[16]  F. Verhaegen,et al.  The radial dose function of low-energy brachytherapy seeds in different solid phantoms: comparison between calculations with the EGSnrc and MCNP4C Monte Carlo codes and measurements. , 2004, Physics in medicine and biology.

[17]  Kirsten Boedeker,et al.  An analysis of MCNP cross-sections and tally methods for low-energy photon emitters. , 2002, Physics in medicine and biology.

[18]  J F Williamson,et al.  Monte Carlo aided dosimetry of the microselectron pulsed and high dose-rate 192Ir sources. , 1995, Medical physics.

[19]  C. Ling,et al.  Using measured dose distribution data of the Fletcher-Suit-Delclos colpostat in brachytherapy treatment planning. , 1987, International journal of radiation oncology, biology, physics.

[20]  R. Nath,et al.  Tissue inhomogeneity correction for brachytherapy sources in a heterogeneous phantom with cylindrical symmetry. , 1992, Medical physics.

[21]  D. Baltas,et al.  An analytical dosimetry model as a step towards accounting for inhomogeneities and bounded geometries in 192Ir brachytherapy treatment planning. , 2003, Physics in medicine and biology.